Preclin Biosystems

Preclin Biosystems AG operates as a specialized preclinical CRO providing in vivo testing services for drug developers, primarily in the inflammatory and infectious disease spaces. The company's value proposition lies in its customizable platform designed to de-risk and accelerate early-stage therapeutic development by offering critical efficacy and safety data. As a private, likely pre-revenue service provider, its growth is tied to securing partnerships and client projects from biopharma companies. Key near-term activities, as of 2020, involved business development through major European and US biotech partnering conferences.

A customizable in vivo preclinical testing platform specializing in models of chronic inflammatory and infectious diseases, offering integrated services for mechanism of action studies, PK/PD/regimen optimization, efficacy testing, and safety assessment.

Preclin Biosystems competes in the global preclinical CRO market against large, full-service players (e.g., Charles River Laboratories, Labcorp) and numerous small, specialized boutiques. Its differentiation is its focused expertise in complex inflammatory and infectious disease models and a customizable service approach, competing on scientific depth and client collaboration rather than scale.